Short Interest in Venus Concept Inc. (NASDAQ:VERO) Expands By 113.1%

Venus Concept Inc. (NASDAQ:VERO) saw a large increase in short interest in December. As of December 31st, there was short interest totaling 199,499 shares, an increase of 113.1% from the December 15th total of 93,597 shares. Based on an average daily trading volume, of 4,414,860 shares, the short-interest ratio is currently 0.0 days. Currently, 19.5% of the shares of the stock are sold short. Currently, 19.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,414,860 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Venus Concept in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Venus Concept Stock Performance

Shares of VERO stock opened at $1.44 on Thursday. Venus Concept has a twelve month low of $1.39 and a twelve month high of $14.50. The stock has a market cap of $2.04 million, a price-to-earnings ratio of -0.03 and a beta of -0.04. The company’s 50-day moving average price is $1.78 and its 200-day moving average price is $2.18. The company has a current ratio of 0.90, a quick ratio of 0.59 and a debt-to-equity ratio of 1.59.

Venus Concept (NASDAQ:VERO) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($12.14) earnings per share for the quarter, missing the consensus estimate of ($3.61) by ($8.53). The firm had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.48 million. Venus Concept had a negative net margin of 92.76% and a negative return on equity of 1,904.25%.

About Venus Concept

Venus Concept Ltd. (NASDAQ: VERO) is a Canada-based medical aesthetic device company that designs, develops and commercializes minimally and noninvasive solutions for face and body rejuvenation. The company’s core product portfolio leverages proprietary technologies such as multi-polar radio frequency, pulsed electromagnetic fields and intense pulsed light to offer treatments for skin tightening, body contouring, wrinkle reduction and vascular lesion removal.

Among its flagship offerings are the Venus Legacy platform, which combines radio frequency and electromagnetic pulses for cellulite reduction and circumferential reduction, and the Venus Versa system, a multi-application device for facial revitalization, acne treatment, hair removal and photorejuvenation.